Hanmi Pharm. Co., Ltd. (KRX:128940)

Market Cap	4.50T
Revenue (ttm)	1.47T
Net Income (ttm)	107.35B
Shares Out	12.68M
EPS (ttm)	8,465.57
PE Ratio	41.88
Forward PE	26.57
Dividend	1,250.00 (0.35%)
Ex-Dividend Date	n/a

Volume	118,221
Average Volume	134,279
Open	363,000
Previous Close	360,500
Day's Range	354,500 - 363,500
52-Week Range	214,500 - 396,500
Beta	0.67
RSI	59.08
Earnings Date	Oct 29, 2025

About Hanmi Pharm.

Hanmi Pharm. Co., Ltd., a biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally. It focuses on research areas with high unmet medical needs, including obesity, metabolism, oncology, and rare diseases. The company’s products include Gugutams, a urological combination therapy combining two active ingredients: tamsulosin, a treatment for Obstructive Prostatic Growth (OPG), and tadalafil, a treatment for erectile dysfunction (ED). The company ha...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1973
• Employees: 2,343
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 128940

Financial Performance

In 2024, Hanmi Pharm.'s revenue was 1.50 trillion, an increase of 0.31% compared to the previous year's 1.49 trillion. Earnings were 121.32 billion, a decrease of -17.04%.